List of 24 unqualified Ginkgo biloba leaf production enterprises announced

According to the announcement of the State Food and Drug Administration, 24 pharmaceutical companies that bought illegal Ginkgo biloba extract from Guilin Daxing Pharmaceutical Co., Ltd. are:

Hebei Zhuozhou Dongle Pharmaceutical Co., Ltd.; Shanxi Ganyuan Pharmaceutical Group Co., Ltd. and Shanxi Ruifulai Pharmaceutical Co., Ltd. in Shanxi Province; Liaoning Shengsheng Pharmaceutical (Group) Co., Ltd. Liaoning Pharmaceutical Branch; Heilongjiang Tianhong Pharmaceutical Co., Ltd.; Anhui Shengying Pharmaceutical Co., Ltd. and Wuhu Luye Pharmaceutical Co., Ltd. in Anhui Province;

Shandong Luxi Pharmaceutical Co., Ltd. and Yantai Rongchang Pharmaceutical Co., Ltd. in Shandong Province; Shi Ming Pharmaceutical Co., Ltd.; Hunan Fangsheng Pharmaceutical Co., Ltd., Hunan Kangerjia Pharmaceutical Co., Ltd., Hunan Warner Pharmaceutical Co., Ltd. and Hunan Hengwei Pharmaceutical Co., Ltd. in Hunan Province; Guangdong Ililuoding Pharmaceutical Co., Ltd. and Guangdong Xinfeng Pharmaceutical Co., Ltd. in Guangdong Province;

Guangxi Wuzhou Dakang Pharmaceutical Co., Ltd. and Guangxi Guilin Honghui Pharmaceutical Co., Ltd.; Hainan Haikou Qi Li Pharmaceutical Co., Ltd., Hainan Lihai Pharmaceutical Co., Ltd. and Hainan Jindao Pharmaceutical Factory; Sichuan Chengdu Senke Pharmaceutical Co., Ltd. and Chengdu Yongkang Pharmaceutical Co., Ltd.; Yunnan Baiyao Group Yunnan Traditional Chinese Medicine Resources Company.

Extended data:

In 20 15, the national spot check found that more than half of the domestic ginkgo production enterprises were unqualified;

On July 20 15, the State Food and Drug Administration of the United States published the results of spot checks on Ginkgo biloba drugs twice. Among the domestic 104 enterprises related to the production of Ginkgo biloba drugs, 55 enterprises produced unqualified Ginkgo biloba drugs, accounting for more than half of all Ginkgo biloba production enterprises. Among them, there are 6 in Jiangsu, and Jiangsu Chenpai Pharmaceutical, Jiangsu Mafei Pharmaceutical, Jiangsu Runbang Pharmaceutical and Nanjing Yiheng have been on the "black list" twice.

On July 2, the Food and Drug Administration released the first batch of special supervision and sampling results of Ginkgo biloba drugs, and the Ginkgo biloba drugs produced by four Jiangsu pharmaceutical companies were unqualified. Among them, Jiangsu Chenpai Pharmaceutical Co., Ltd. failed in two batches of Ginkgo biloba dispersible tablets, and Jiangsu Mafei Pharmaceutical Co., Ltd., Jiangsu Runbang Pharmaceutical Co., Ltd. and Nanjing Yiheng Pharmaceutical Co., Ltd. failed in ginkgo biloba leaves, reaching 1, 5 and 4 batches respectively.

On July 3 1, the results of the second batch of special supervision of Ginkgo biloba drugs released by the Food and Drug Administration showed that unqualified drugs were detected in 1 18 batches of drugs, involving 3 pharmaceutical manufacturers, including Baiyi Pharmaceutical, Fangsheng Pharmaceutical, Ganyuan Pharmaceutical and Yabao.

Among them, there are six pharmaceutical companies involved in Jiangsu, namely Changzhou Lanling Pharmaceutical, Jiangsu Pai Cheng Pharmaceutical, Jiangsu Pharmaceutical, Jiangsu Runbang Pharmaceutical, Wu Traditional Chinese Medicine Suzhou Pharmaceutical Factory and Nanjing Yiheng Pharmaceutical. However, the unqualified batches of Ginkgo biloba capsules produced by Changzhou Lanling Pharmaceutical Co., Ltd. are as high as 10, while Jiangsu Chenpai Pharmaceutical Co., Ltd. has 2 batches of Ginkgo biloba dispersible tablets and 6 batches of Ginkgo biloba.

Notice of China Food and Drug Administration-China Food and Drug Administration on the illegal production and sale of Ginkgo biloba drugs by Guilin Daxing Pharmaceutical Co., Ltd. and other enterprises?

People's Daily Online-More than half of the drugs produced by domestic ginkgo companies are unqualified, including 6 from the Soviet Union.